Filling the need for trusted information on national health issues

Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.

  • Your Selections:

Refine Results

date

Topics

Content Type

Tags

Data Note: Prescription Drugs and Older Adults

This data note explores the attitudes and experiences of older adults, ages 65 and up, when it comes to prescription drugs and related policy proposals being discussed. Experiences across different demographic groups are explored, such as household income and health status.

Issue Brief Read More

What Steps Are Washington Policymakers Pursuing to Control Medicare Prescription Drug Spending?

As policymakers in Washington discuss ways to curb the rising cost of prescription drugs, KFF has released a summary and analysis of proposals and recently finalized initiatives that affect Medicare prescription drug spending.  Medicare, the federal health program that covers more than 60 million seniors and younger people with disabilities,…

News Release Read More

A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries

In response to higher drug spending growth and heightened attention to drug prices, policymakers have proposed a variety of policy initiatives to lower the cost of prescription drugs in Medicare. This brief examines in detail the range of proposals offered by the Trump Administration and members of Congress for lowering the cost of prescription drugs, their known effects on the federal budget, and their potential implications for beneficiaries and other stakeholders.

Issue Brief Read More
The Henry J. Kaiser Family Foundation

A Small Group of Patients Account for a Whole Lot of Spending

You have heard about the 5% of the population responsible for 50% of spending. Meet the 1.3%–persistent high spenders with very complex medical needs responsible for 20%. Drew Altman discusses this and possible ways to help them, read the Axios column.

Perspective Read More
The Henry J. Kaiser Family Foundation

Explainer Video Breaks Down Prescription Drug Rebates and Why They Matter in the Debate About Prescription Drug Costs

A new KFF animation explains how rebates for prescription drugs work, including how they are determined, who benefits from them, how they affect spending by insurers and consumers and the role of pharmacy benefit managers in the process. The Trump Administration had proposed banning such rebates in Medicare Part D,…

News Release Read More

Prescription Drug Rebates, Explained

This animation explains how rebates for prescription drugs work and why they matter in the debate about lowering drug costs. The video breaks down how prescription drug rebates are determined, who benefits from them, how they affect spending by insurers and consumers and the role of pharmacy benefit managers in…

Video Read More

What’s the Latest on Medicare Drug Price Negotiations?

In response to higher drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing Medicare to negotiate the price of prescription drugs. This issue brief provides a short history of this proposal, describes various approaches, and assessments of their potential savings from the Congressional Budget Office (CBO), and considers the prospects for action in the future.

Issue Brief Read More

How Many Medicare Part D Enrollees Had High Out-of-Pocket Drug Costs in 2017?

The Medicare Part D prescription drug benefit has helped improve the affordability of medications for people with Medicare. Yet Part D enrollees can face relatively high out-of-pocket costs because the Part D benefit does not have a hard cap on out-of-pocket spending. This analysis presents the latest data on out-of-pocket drug spending among Medicare Part D enrollees without low-income subsidies who have costs above the catastrophic coverage threshold.

Issue Brief Read More

Data Note: Americans’ Challenges with Health Care Costs

This data note summarizes our most recent polling on the public’s experiences with and worries about health care costs, and it highlights where Americans place costs on their list of health care issues for the government to address and for political candidates to discuss.

Issue Brief Read More